Kiniksa's Heart's Home Campaign Puts ARCALYST Growth Prospects In Focus [Yahoo! Finance]
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA)
Last kiniksa pharmaceuticals international, plc - class a ordinary shares earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) has launched Heart's Home, a direct to consumer campaign for ARCALYST. The initiative focuses on raising awareness of recurrent pericarditis and highlighting ARCALYST as a treatment option. ARCALYST is currently the only FDA approved therapy for recurrent pericarditis. Kiniksa Pharmaceuticals International, traded as NasdaqGS:KNSA, focuses on therapies for patients with serious inflammatory and autoimmune conditions. With Heart's Home, the company is moving beyond traditional physician focused outreach to speak directly to patients living with recurrent pericarditis, a niche but serious cardiac condition. That aligns with a broader industry pattern in which specialty drug developers use targeted campaigns to build awareness around underdiagnosed diseases. For you as an investor, the launch of Heart's Home is less about advertising flair and more about how Kiniksa aims to build long term demand for ARCALYST in its approved
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KNSA
News
- What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Wedbush from $53.00 to $58.00. They now have an "outperform" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent PericarditisGlobeNewswire
KNSA
Earnings
- 2/24/26 - Miss
KNSA
Sec Filings
- 4/16/26 - Form ARS
- 4/16/26 - Form DEFA14A
- 4/16/26 - Form DEF
- KNSA's page on the SEC website